

December 18, 2014

Relmada Therapeutics Announces Results of Annual Shareholders Meeting

All Items on the Proxy Received Shareholder Approval

NEW YORK, Dec. 18, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced the results of its annual general meeting of shareholders held today.

"This was a transformational year in Relmada's history and it set the stage for a promising future for our company," said Sergio Traversa, chief executive officer of Relmada. "Over the past year, we have executed on key financial, human resource and clinical development objectives that position Relmada for long-term success, with a significant and notable event being our transition to a public company. We look forward to transparently and frequently updating our shareholders and the market as we execute our strategic plan."

All items on the proxy received shareholder approval, which included the election of four incumbent directors - Sandesh Seth, Sergio Traversa, Shreeram Agharkar, Ph.D., Nabil M. Yazgi, M.D., approval of the company's 2014 Stock Plan and Equity Incentive Plan, an amendment to the company's Articles of Incorporation to include staggered board provisions, approval of the compensation for named executive officers, approval of the frequency of the advisory vote of three years for the named executive officers, and ratification of the appointment by the Board of Directors of GBH CPAs, PC as the company's independent auditors.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements". These statements are based on management's current expectations and involve risks and uncertainties, which may cause

actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

Michael Becker, SVP of Finance and Corporate Development

Relmada Therapeutics Inc.

Tel: 212-702-7169

mbecker@relmada.com

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-results-of-annual-shareholders-meeting-300012229.html>

SOURCE Relmada Therapeutics, Inc.